Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Experts Dissect 3 Practice-Changing Studies for Newly Diagnosed CLL

Christina T. Loguidice
Published: Monday, Apr 01, 2019
Dr. William G. Wierda

William G. Wierda, MD, PhD
More and more, the role of chemoimmunotherapy (CIT) continues to diminish in the first-line treatment of patients with chronic lymphocytic leukemia (CLL), as the many new agents and combinations introduced in the past 5 years have shown promise in clinical trials and made their way into clinics.1,2 Historically, CIT has been the standard first-line treatment for patients with CLL.

Additionally, several panelists noted that they are looking forward to learning the findings of the CLL14 study, which is evaluating the combination of venetoclax (Venclexta) and obinutuzumab versus CIT for patients who have not received prior treatment. The FDA is reviewing a supplemental application for the regimen.


The international, randomized, open-label, phase III iLLUMINATE study compared the safety and efficacy of ibrutinib plus obinutuzumab (ibr-G) with chlorambucil plus obinutuzumab (clb-G) as a first-line treatment for CLL or small lymphocytic lymphoma (SLL).3,4 Patients were aged ≥65 years or <65 years with significant comorbidities or high-risk genomic features (ie, Cumulative Illness Rating Scale score >6, creatinine clearance <70 mL/min, and/or del[17p] or TP53 mutation).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication